ArticleRSC advances2025
Sensitive determination of valganciclovir
Article in RSC advances, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This study presents the development of an electrochemical sensor based on a carbon paste electrode modified with nickel-cobalt multilayer nanowires (Co-Ni(MLNW)/CPE) for the detection of valganciclovir, an antiviral drug. The sensor was fabricated using an electrochemical deposition method, and its electrochemical behavior was investigated through cyclic voltammetry (CV) and differential pulse voltammetry (DPV). The influence of pH on the sensor's performance was extensively studied, revealing that the redox reaction of valganciclovir (VGCV) involves proton exchange, making pH optimization crucial. The results demonstrated that the sensor exhibited a wide linear range from 0.1 to 2000 nM, with a low detection limit of 0.03 nM at pH 7, the optimal condition for VGCV detection. Additionally, the sensor showed excellent stability, reproducibility, and selectivity, with negligible interference from common ions and biological molecules. The sensor's applicability was further validated through the determination of VGCV in human plasma samples, achieving a high recovery rate of 97.9%. These findings indicate that the proposed Co-Ni(MLNW)/CPE sensor is a promising tool for the accurate, sensitive, and reliable determination of VGCV in clinical and pharmaceutical settings.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.